Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells
Neuroblastoma (NB) is the most common extracranial solid tumor in children and, in the high-risk group, has a 5-year mortality rate of ~50%. The high mortality rate and significant treatment-related morbidities associated with current standard of care therapies belie the critical need for more toler...
Main Authors: | Kevin O. McNerney, Spyridon A. Karageorgos, Michael D. Hogarty, Hamid Bassiri |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00873/full |
Similar Items
-
The role of NK and NKT cells in the pathogenesis and improvement of multiple sclerosis following disease‐modifying therapies
by: Alireza Ahmadi, et al.
Published: (2022-01-01) -
iNKT: A new avenue for CAR-based cancer immunotherapy
by: Yilin Liu, et al.
Published: (2022-03-01) -
Heightened metabolic responses in NK cells from patients with neuroblastoma suggests increased potential for immunotherapy
by: Karen Slattery, et al.
Published: (2022-10-01) -
How Lipid-Specific T Cells Become Effectors: The Differentiation of iNKT Subsets
by: Haiguang Wang, et al.
Published: (2018-06-01) -
Strategies for Potentiating NK-Mediated Neuroblastoma Surveillance in Autologous or HLA-Haploidentical Hematopoietic Stem Cell Transplants
by: Cristina Bottino, et al.
Published: (2022-09-01)